金涌，教授，碩士生導(dǎo)師

1969年10月生，安徽醫(yī)科大學(xué)藥學(xué)院院長。安徽醫(yī)科大學(xué)教學(xué)名師。中國藥學(xué)會(huì)和藥理學(xué)會(huì)會(huì)員，安徽省藥理學(xué)會(huì)理事，安徽省藥學(xué)會(huì)藥物分析專業(yè)委員會(huì)和臨床試驗(yàn)專業(yè)委員會(huì)副主任委員，藥劑學(xué)和臨床藥理專業(yè)委員會(huì)常務(wù)委員，《安徽醫(yī)藥》編委。

長期從事生物藥劑學(xué)和體內(nèi)藥物分析學(xué)研究，主要研究領(lǐng)域?yàn)榉枷銦N受體與肝臟疾病。作為主要參加者參與多項(xiàng)國家自然科學(xué)基金、國家重大基礎(chǔ)研究前期（973前期）研究專項(xiàng)、國家科技部863立項(xiàng)項(xiàng)目等研究。

主持省部級科研項(xiàng)目多項(xiàng)，近年來發(fā)表學(xué)術(shù)論文50余篇，其中SCI收錄30余篇，先后獲安徽省自然科學(xué)二、三等獎(jiǎng)各一項(xiàng)。安徽省教學(xué)成果特等獎(jiǎng)和一等獎(jiǎng)各一項(xiàng)。

主要代表作：

Xia H, Zhu X, Zhang X, Jiang H, Li B, Wang Z, Li D, Jin Y. Alpha-naphthoflavone attenuates non-alcoholic fatty liver disease in oleic acid-treated HepG2 hepatocytes and in high fat diet-fed mice. Biomed Pharmacother. 2019 Oct; 118: 109287. 

Zhu XY, Xia HG, Wang ZH, Li B, Jiang HY, Li DL, Jin R, Jin Y. In vitro and in vivo approaches for identifying the role of aryl hydrocarbon receptor in the development of nonalcoholic fatty liver disease. Toxicol Lett. 2020 Feb 1; 319: 85-94.

Cao Y, Gao H, Xia H, Zhu X, Li B, Zhou X, Jin Y. Development and Evaluation of a Water-in-oil Microemulsion Formulation for the Transdermal Drug Delivery of Teriflunomide (A771726). Chem Pharm Bull (Tokyo). 2019; 67(8): 786-794.

Xu M, Yu Q, Zhao Q, Chen W, Lin Y, Jin Y. Development and in vitro-in vivo evaluation of a water-in-oil microemulsion formulation for the oral delivery of troxerutin. Drug Dev Ind Pharm. 2016;42(2):280-7.

Gao H, Cao Y, Xia H, Zhu X, Jin Y. CYP4A11 is involved in the development of nonalcoholic fatty liver disease via ROSinduced lipid peroxidation and inflammation. Int J Mol Med. 2020 Apr;45(4):1121-1129.

Chen W, Lin YJ, Zhou XY, Chen H, Jin Y. Rosiglitazone protects rat liver against acute liver injury associated with the NF-κB signaling pathway. Can J Physiol Pharmacol. 2016 Jan;94(1):28-34.